Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24810732 | 0.81 | PDE4D (0.31) | PDE2APDE1BPDE1CPDE1A | |
| SCHEMBL24809776 | 0.74 | HPGDS (0.35) | PDE10AF2PLGPLAUPLAT | |
| SCHEMBL24810588 | 0.72 | TDP1 (0.36) | — | |
| SCHEMBL24810730 | 0.70 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL24809762 | 0.68 | PDE4D (0.34) | — | |
| SCHEMBL24809474 | 0.65 | GBA1 (0.35) | — | |
| SCHEMBL24809767 | 0.64 | NAMPT (0.40) | — | |
| SCHEMBL24812043 | 0.62 | TRPV3 (0.38) | PDE2A | |
| SCHEMBL23123505 | 0.59 | F2 (0.34) | F2PLGPLAUPLATKLK1 | |
| SCHEMBL24809766 | 0.58 | BCHE (0.34) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, CLN6 | PDE10A 2939/4885F2 4826/4885PLG 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.